-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, F0tQOktm02+Rsg2ssOgMWkKNYbzYI5XWnMy1ojKK+CyiRYzCGYMRVcBKmnTLLGCx nuDKUHKbxe4GF/3jnvaJ/w== 0001104659-08-040949.txt : 20080619 0001104659-08-040949.hdr.sgml : 20080619 20080619160734 ACCESSION NUMBER: 0001104659-08-040949 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080616 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20080619 DATE AS OF CHANGE: 20080619 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19700 FILM NUMBER: 08907947 BUSINESS ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 a08-16968_18k.htm 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  June 16, 2008

 

AMYLIN PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or Other Jurisdiction of
Incorporation)

 

0-19700

(Commission File Number)

 

33-0266089

(I.R.S. Employer Identification No.)

 

9360 Towne Centre Drive

San Diego, California 92121

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code:  (858) 552-2200

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CRF 240.13e-4(c))

 

 


 

Item 1.01.  Entry into a Material Definitive Agreement.

 

On June 16, 2008, Amylin Pharmaceuticals, Inc. and Mallinckrodt Inc. entered into an Amendment to their Exenatide Manufacturing Agreement, or the Amendment, which amends the manufacturing agreement between the parties, dated October 1, 2003, pursuant to which Mallinckrodt manufactures and supplies to Amylin bulk exenatide, the active ingredient in BYETTA® (exenatide) injection.  Under the terms of the Amendment, the termination date of agreement has been extended for a period of four years to September 30, 2012.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

AMYLIN PHARMACEUTICALS, INC.

 

 

 

 

Dated:  June 19, 2008

By:

  /s/ LLOYD A. ROWLAND

 

 

Lloyd A. Rowland

 

 

Vice President, Governance and Compliance, and
Secretary

 

3

 -----END PRIVACY-ENHANCED MESSAGE-----